Takeda
-
Takeda and UNGCNI join hands to strengthen access to rare disease treatment in India
Bangalore, 9 May 2022: In November 2021, Takeda Pharmaceutical Company Limited, a global values-based, R&D-driven biopharmaceutical leader, together with UNGCNI…
Read More » - Business Wire
New Data from the Phase 3 HELP Study™ Open-Label Extension Evaluating Safety and Efficacy of TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
− Analysis of Safety and Efficacy for up to 2.5 years with TAKHYZRO is Consistent with Initial Period of Treatment,…
Read More » - Business Wire
Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2020
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F…
Read More » - Business Wire
Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results
− Takeda’s dengue vaccine candidate (TAK-003) prevented 83.6% of hospitalizations and 62.0% of dengue illness overall, with no identified important…
Read More » - Health
Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan
Osaka, Japan: − The Ministry of Health, Labour and Welfare (MHLW) Grants Regulatory Approval of Moderna’s COVID-19 Vaccine (COVID-19 Vaccine…
Read More » - Health
U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treat
Osaka, Japan: − If Approved, Maribavir Will Be the First and Only Treatment Indicated for Post-Transplant Cytomegalovirus (CMV) Infection in…
Read More » - Business Wire
Takeda Manufacturing Facilities in Japan and Ireland Recognized With Category Awards for 2021 Facilities of the Year
Both Awards, Issued by the International Society for Pharmaceutical Engineering (ISPE), Underscore Takeda’s Leadership in Digital and Innovative Technologies New…
Read More » - Business
Takeda Completes Sale of Its Japan Consumer Health Care Business Unit to Blackstone
Osaka, Japan: Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of Takeda Consumer…
Read More » -
Takeda Completes Sale of Select OTC and Non-Core Assets to Orifarm
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of…
Read More » - Business Wire
Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
− European Medicines Agency to Conduct First-Ever Parallel Assessment of a Medicinal Product, Takeda’s Dengue Vaccine Candidate (TAK-003), for use…
Read More » - Health
Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine
Osaka, Japan: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and…
Read More » - Business
Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema Attacks
Osaka, Japan: — Lanadelumab is an investigational monoclonal antibody for the preventive treatment of hereditary angioedema (HAE) in patients 12…
Read More » - Business
Takeda’s Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade1
Osaka, Japan & Cambridge, Mass., United States: Aiming for Revenues of JPY 1 Trillion (approximately US$9 Billion2) by FY2030 Double-Digit…
Read More » - Business
Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology Portfolio
Osaka, Japan & Brisbane, Calif., United States: Acquisition expands Takeda’s immuno-oncology portfolio with two development candidates and Maverick’s conditionally active…
Read More » - Health
PPHF, Niti Aayog Co-host Global Rare Disease Conference on International Rare Disease Day
Over 7000 rare diseases have been identified globally, only 5% of these have identified treatments. 450 rare diseases have been…
Read More » - Health
Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
Osaka, Japan & New York, United States: − Ovid eligible to receive up to $856M in payments, including a $196M…
Read More » - Business
Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited
Osaka, Japan: sset transfer furthers Takeda’s global strategy to focus on five key business areas Takeda will continue to manufacture…
Read More » - Business
Takeda FY2020 Q3 Results Demonstrate Growth Acceleration and Continued Resilience; Full-Year Management Guidance for FY2020 Confirmed, Forecast Raised for Free Cash Flow and Reported EPS
Osaka, Japan: FY2020 Q3 Year-to-Date Results Driven by 15% Underlying Revenue Growth of 14 Global Brands (e.g., ENTYVIO +24.0%, TAKHZYRO…
Read More » - Business
Data at EAHAD 2021 Highlight Value of Takeda’s Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements
Osaka, Japan: − Seven Year Data Reinforce Long-term Efficacy and Safety Review of ADVATE (Antihemophilic Factor [Recombinant]) − Abstracts Support…
Read More » - Business
Takeda Completes Sale of TachoSil® to Corza Health
Osaka, Japan: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has completed the previously announced sale of TachoSil® Fibrin Sealant Patch…
Read More » -
Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma
Osaka, Japan: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of…
Read More » - Health
Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based Chemotherapy
Osaka, Japan & Cambridge, Mass., United States: Mobocertinib, an oral targeted therapy, demonstrated clinically meaningful responses, with a confirmed objective…
Read More » - United States
Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index
Osaka, Japan & Cambridge, Mass., United States: Company Ranked Sixth Overall and Leads the Pharmaceutical Industry in Governance of Access…
Read More » - Business
Takeda Named Global Top Employer for Fourth Consecutive Year
Osaka, Japan & Cambridge, Mass., United States: – Achieved Global Recognition in Addition to Certifications in Four Regions and 38…
Read More » - Business
Julie Dehaene-Puype and Erik Nordkamp appointed as new regional Commercial Officers for Mundipharma
England, Cambridge, United Kingdom: The Mundipharma network of independently associated companies today announced two new appointments to their Executive Committee…
Read More » - Business
Takeda to Present at The 39th Annual J.P. Morgan Healthcare Conference
Osaka, Japan & Cambridge, Mass., United States: Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) will present virtually at the…
Read More » - Health
U.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML
Osaka, Japan & Cambridge, Mass., United States: – Updated ICLUSIG Label will Prove Practice-Changing, Expanding Indication to CP-CML Patients with Resistance…
Read More » - Health
Takeda’s Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade
Osaka, Japan: Company Aiming for Mid-Single-Digit Revenue CAGR Over Next Decade Amounting to JPY5 Trillion ($47 Billion) by FY20301 Wave…
Read More » - Business
Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema
Shanghai, China & Osaka, Japan: − TAKHZYRO is the first approved modern therapy for the preventive treatment of hereditary angioedema…
Read More »
- 1
- 2